Pharmaceuticals firm RPG Life Sciences Announced Q1FY23 Result : Q1 FY23 Revenue from operations grew by 19 % YoY and 24% QoQ. PBT grew by 30% YoY and 130% QoQ. RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 30% YoY and by 130% QoQ for Q1 FY23. Revenue from operations at Rs 128.93 crores registered a growth of 19% YoY and a growth of 24% QoQ for Q1 FY23. The Company maintained the upward trajectory in EBITDA margin, which improved from 21.6% to 22.5% YoY Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q1 FY23, the overall performance of the Company continued to be strong despite the geo-political challenges impacting supply chain and costs. Revenue and PBT grew by 19% and 30% respectively YoY EBITDA margin retained its upward trajectory growing from 21.6% to 22.5% YoY. Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently better than the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. We have successfully forayed into a new therapy area - Rheumatology, which is strengthening our Specialty segment. Salesforce productivity continues to register healthy upward momentum. International Formulations business has shown a robust recovery while API business continue to register growth. Our unique digital initiative, RPGServ, is having impressive traction in physician connect and engagement. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.” Result PDF
Pharmaceuticals company RPG Life Sciences declares Q3FY22 result: 9M FY22 Revenue from operations grew by 13% and PBT grew by 39% with EBITDA margin expanding from 19.5% to 22.2% YoY RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 21% YoY for Q3 FY22, maintaining the upward trajectory in EBITDA margins, which improved from 19.9% to 21.4% YoY. Revenue from operations at Rs 115.58 crores registered a growth of 7% YoY for Q3 FY22. For 9M FY22, the company posted a jump in PBT by 39% YoY and recorded EBITDA margin expansion from 19.5% to 22.2% YoY. Revenue from operations at Rs 336.36 crores registered a growth of 13% YoY for 9M FY22. Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “I am pleased to share that in Q3 FY22, we continued to deliver a robust performance. Revenue and PBT grew by 7% and 21% respectively YoY. EBITDA margins’ upward trajectory continued, growing from 19.9% to 21.4% YoY. The Company continues to remain debt free with highest-ever net cashflow generated from operations in 9M FY22. Domestic Formulations business recorded a robust growth both in value and volumes - significantly better than the market. While life cycle management initiatives helped legacy brands register healthy growth, our new product portfolio is also witnessing an impressive uptake. We have successfully forayed into a new segment - Rheumatology, which is strengthening our endeavour of expanding into the Specialty segment. Salesforce productivity continues to register upward momentum. API business also recorded robust growth. In the International Formulations business, our growth was somewhat subdued due to the political unrest in one of our key markets, Myanmar. However, rest of the international business reflected strong performance supported by new launches. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.” Result PDF